Literature DB >> 16861689

Enhanced immunogenicity and protective efficacy with the use of interleukin-12-encapsulated microspheres plus AS01B in tuberculosis subunit vaccination.

Sang-Jun Ha1, Su-Hyung Park, Hye-Ju Kim, Seung-Chul Kim, Hyang-Ju Kang, Eun-Gae Lee, Soon-Geon Kwon, Byong-Moon Kim, Sung-Hee Lee, Won-Bae Kim, Young-Chul Sung, Sang-Nae Cho.   

Abstract

Tuberculosis subunit vaccines codelivered with interleukin-12 (IL-12)-encapsulated microspheres (IL-12EM) are designed for a sustained release of IL-12 and could induce strong Th1 immune responses specific to Ag85A and ESAT-6. The adjuvant combination of IL-12EM plus AS01B was a more efficient way to induce a sustained Th1 immunity and protection against Mycobacterium tuberculosis.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16861689      PMCID： PMC1539587          DOI： 10.1128/IAI.01781-05

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  30 in total

1.  In vitro and in vivo release properties of brilliant blue and tumour necrosis factor-alpha (TNF-alpha) from poly(D,L-lactic-co-glycolic acid) multiphase microspheres.

Authors:  M Iwata; Y Nakamura; J W McGinity
Journal:  J Microencapsul       Date:  1999 Nov-Dec       Impact factor: 3.142

2.  Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6.

Authors:  A Weinrich Olsen; L A van Pinxteren; L Meng Okkels; P Birk Rasmussen; P Andersen
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

3.  Preferential localization of effector memory cells in nonlymphoid tissue.

Authors:  D Masopust; V Vezys; A L Marzo; L Lefrançois
Journal:  Science       Date:  2001-03-01       Impact factor: 47.728

4.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.

Authors:  F Sallusto; D Lenig; R Förster; M Lipp; A Lanzavecchia
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

5.  Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.

Authors:  K A Bojang; P J Milligan; M Pinder; L Vigneron; A Alloueche; K E Kester; W R Ballou; D J Conway; W H Reece; P Gothard; L Yamuah; M Delchambre; G Voss; B M Greenwood; A Hill; K P McAdam; N Tornieporth; J D Cohen; T Doherty
Journal:  Lancet       Date:  2001-12-08       Impact factor: 79.321

6.  Improved immunogenicity and protective efficacy of a tuberculosis DNA vaccine encoding Ag85 by protein boosting.

Authors:  A Tanghe; S D'Souza; V Rosseels; O Denis; T H Ottenhoff; W Dalemans; C Wheeler; K Huygen
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

7.  The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge.

Authors:  L Stobie; S Gurunathan; C Prussin; D L Sacks; N Glaichenhaus; C Y Wu; R A Seder
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

8.  In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity.

Authors:  N K Egilmez; Y S Jong; M S Sabel; J S Jacob; E Mathiowitz; R B Bankert
Journal:  Cancer Res       Date:  2000-07-15       Impact factor: 12.701

9.  Persistence and turnover of antigen-specific CD4 T cells during chronic tuberculosis infection in the mouse.

Authors:  Gary M Winslow; Alan D Roberts; Marcia A Blackman; David L Woodland
Journal:  J Immunol       Date:  2003-02-15       Impact factor: 5.422

10.  Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.

Authors:  Hank C Hill; Thomas F Conway; Michael S Sabel; Yong S Jong; Edith Mathiowitz; Richard B Bankert; Nejat K Egilmez
Journal:  Cancer Res       Date:  2002-12-15       Impact factor: 12.701
View more
  9 in total

Review 1.  Interleukin-12 and tuberculosis: an old story revisited.

Authors:  Andrea M Cooper; Alejandra Solache; Shabaana A Khader
Journal:  Curr Opin Immunol       Date:  2007-08-16       Impact factor: 7.486

Review 2.  Synthetic nanovaccines for immunotherapy.

Authors:  Min Luo; Layla Z Samandi; Zhaohui Wang; Zhijian J Chen; Jinming Gao
Journal:  J Control Release       Date:  2017-03-21       Impact factor: 9.776

Review 3.  Particle-mediated delivery of cytokines for immunotherapy.

Authors:  David A Christian; Christopher A Hunter
Journal:  Immunotherapy       Date:  2012-04       Impact factor: 4.196

4.  Interleukin 12B (IL12B) genetic variation and pulmonary tuberculosis: a study of cohorts from The Gambia, Guinea-Bissau, United States and Argentina.

Authors:  Gerard A J Morris; Digna R Velez Edwards; Philip C Hill; Christian Wejse; Cyrille Bisseye; Rikke Olesen; Todd L Edwards; John R Gilbert; Jamie L Myers; Martin E Stryjewski; Eduardo Abbate; Rosa Estevan; Carol D Hamilton; Alessandra Tacconelli; Giuseppe Novelli; Ercole Brunetti; Peter Aaby; Morten Sodemann; Lars Østergaard; Richard Adegbola; Scott M Williams; William K Scott; Giorgio Sirugo
Journal:  PLoS One       Date:  2011-02-09       Impact factor: 3.240

5.  Co-immunization of plasmid DNA encoding IL-12 and IL-18 with Bacillus Calmette-Guérin vaccine against progressive tuberculosis.

Authors:  Bo-Young Jeon; Hyungjin Eoh; Sang-Jun Ha; Hyeeun Bang; Seung-Cheol Kim; Young-Chul Sung; Sang-Nae Cho
Journal:  Yonsei Med J       Date:  2011-11       Impact factor: 2.759

6.  Synthesis, Characterization, and In Vivo Cytokinome Profile of IL-12-Loaded PLGA Nanospheres.

Authors:  Ryan A Lacinski; Justin E Markel; Jabeen Noore; Hillary G Pratt; Brock A Lindsey
Journal:  J Immunol Res       Date:  2022-04-14       Impact factor: 4.493

7.  IL-12 DNA Displays Efficient Adjuvant Effects Improving Immunogenicity of Ag85A in DNA Prime/MVA Boost Immunizations.

Authors:  María Paula Morelli; María Paula Del Medico Zajac; Joaquín Miguel Pellegrini; Nicolás Oscar Amiano; Nancy Liliana Tateosian; Gabriela Calamante; María Magdalena Gherardi; Verónica Edith García
Journal:  Front Cell Infect Microbiol       Date:  2020-09-23       Impact factor: 5.293

Review 8.  Potential of polymeric particles as future vaccine delivery systems/adjuvants for parenteral and non-parenteral immunization against tuberculosis: A systematic review.

Authors:  Farzad Khademi; Mohammad Derakhshan; Arshid Yousefi-Avarvand; Mohsen Tafaghodi
Journal:  Iran J Basic Med Sci       Date:  2018-02       Impact factor: 2.699

Review 9.  Nanoparticle Vaccines Against Infectious Diseases.

Authors:  Rashmirekha Pati; Maxim Shevtsov; Avinash Sonawane
Journal:  Front Immunol       Date:  2018-10-04       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.